ADVFN US – Market Content Editor
-
Dow Jones, S&P, Nasdaq, Wall Street Futures, Fed Meeting Begins; Paramount Escalates WBD Battle: Here’s What’s Moving Markets
U.S. equity futures were pointing modestly higher early Tuesday as traders braced for what could be a highly debated Federal Reserve decision on Wednesday. Markets were also digesting a dramatic new twist in the bidding war for Warner Bros Discovery (NASDAQ:WBD), fresh policy news affecting Nvidia (NASDAQ:NVDA), and another small pullback in Bitcoin (COIN:BTCUSD). Futures…
-
Stellantis and Bolt Team Up to Roll Out Autonomous Mobility Services Across Europe
Stellantis NV (NYSE:STLA) and Bolt have announced a new partnership aimed at bringing large-scale driverless mobility solutions to European cities, with pilot programs scheduled to launch in 2026 and full industrial production targeted for 2029. The initiative is designed to speed up the adoption of autonomous vehicles across the continent, leveraging the strengths of both…
-
Ford Looks to Renault to Reinforce Its European Operations as Chinese Rivals Gain Ground
Ford (NYSE:F) has enlisted Renault (EU:RNO) as a strategic partner in an effort to strengthen its European business at a time when Chinese automakers are rapidly expanding their global presence. “We know we’re in a fight for our lives in our industry, and no better example than here in Europe,” Ford Chief Executive Officer Jim…
-
EU Opens Antitrust Investigation into Google’s AI Practices
The European Union has initiated a formal antitrust probe into Alphabet’s (NASDAQ:GOOG) Google, examining whether the company’s conduct in the artificial intelligence space may be harming competition. In a statement released Tuesday, the European Commission said it is assessing whether Google has been imposing unfair terms on publishers and content creators, potentially restricting their ability…
-
U.S. Stocks Close Modestly Lower As Fed Meeting Looms
Stocks moved to the upside at the start of trading on Monday but moved lower over the course of the trading session. The major averages pulled back off their early highs and into negative territory. The major averages staged a short-lived recovery attempt in mid-day trading but all ended the day in the red. The…
-
U.S. iPhone upgrade interest at its lowest level in five years, UBS survey shows
Apple (NASDAQ:AAPL) is seeing weakening iPhone purchase intent in the U.S., according to new data from UBS Evidence Lab, even as interest in China unexpectedly improved. The survey, which gathered responses from more than 7,500 smartphone users across five major markets, found that 12-month U.S. iPhone purchase intent slid by roughly 400 basis points to…
-
Chipotle gains after approving $1.8 billion in additional share buybacks
Chipotle Mexican Grill (NYSE:CMG) climbed 2.5% on Monday after disclosing that its Board of Directors approved another $1.8 billion for share repurchases. According to the company’s SEC filing, the authorization—approved on December 4—brings Chipotle’s total remaining buyback capacity to roughly $1.85 billion as of December 5. The move signals a shift in Chipotle’s capital-return strategy.…
-
Castellum rallies after landing key Missile Defense Agency SHIELD contract positions
Castellum, Inc. (AMEX:CTM) rose 5.3% on Monday following news that the company’s subsidiary and joint-venture partners secured spots on the Missile Defense Agency’s SHIELD Multiple Award IDIQ contract vehicle. The cybersecurity and electronic-warfare services firm said that Specialty Systems, Inc., CTM Joint Venture, the C-K2 mentor-protégé JV, and the Epic Specialty Systems mentor-protégé JV all…
-
Sellas Life Sciences rises after reporting encouraging AML clinical results
Sellas Life Sciences Group Inc. (NASDAQ:SLS) advanced 4% in premarket trading Monday after unveiling new Phase 2 data for its investigational therapy SLS009 in acute myeloid leukemia with myelodysplastic syndrome–related changes (AML-MR). In patients who had previously been treated with venetoclax-based regimens, SLS009 — a CDK9 inhibitor — combined with azacitidine and venetoclax produced a…
-
PureTech slides after FDA meeting outlines next steps for IPF program
PureTech Health PLC (NASDAQ:PRTC) dropped 8.1% in Monday’s premarket trading after providing an update on its End-of-Phase 2 discussions with the FDA regarding deupirfenidone, a potential treatment for idiopathic pulmonary fibrosis (IPF). The company said regulators are supportive of moving into a pivotal Phase 3 study and pursuing a 505(b)(2) regulatory pathway through its Founded…